Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study
Modern Rheumatology · 2026
DOI: 10.1093/mr/roag031 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Tsutomu Takeuchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Heterocyclic Compounds, 3-Ring, Methotrexate. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Objective
To evaluate the long-term (5-year) efficacy and safety of upadacitinib monotherapy compared with methotrexate (MTX) monotherapy in Japanese patients with rheumatoid arthritis who were included in the Phase 3 SELECT-EARLY study.
Methods
Japanese patients were randomised 2:1:1:1 to upadacitinib 7.5, 15, or 30 mg daily, or MTX 7.5 mg/week (titrated to ≤15 mg/week). Efficacy assessments through Week 260 are reported as observed for patients receiving continuous upadacitinib or MTX, and by randomised group using non-responder imputation. Treatment-emergent adverse events were collected over 5 years and reported as events per 100 patient-years.
Results
Of the 138 Japanese patients treated, 123 (89%) completed Week 48, and 121 (88%) entered the long-term extension on the study drug. Patients receiving upadacitinib had better overall long-term efficacy outcomes compared with patients receiving MTX. Similarly, treatment with upadacitinib resulted in numerically greater inhibition of structural joint progression through 5 years, relative to MTX. Higher treatment-emergent adverse event rates were observed in the 30 mg upadacitinib group compared with all other treatment groups, and no new safety signals were identified overall.
Conclusion
This subanalysis of the SELECT-EARLY Japanese population corroborates findings from the global study population on the long-term clinical efficacy and safety of upadacitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Keio University School of Medicine, Tokyo, Japan.
- Saitama Medical University, Saitama, Japan.
- Amsterdam University Medical Center, Amsterdam, The Netherlands.
- Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan.
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- AbbVie Inc., North Chicago, IL, United States.
Förderung
- AbbVie
Zitieren
APA
Takeuchi, T., van Vollenhoven, R., Ueki, Y., Atsumi, T., Meerwein, S., Bu, X., Hirata, K., & Strand, V. (2026). Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study. Modern Rheumatology. https://doi.org/10.1093/mr/roag031
Vancouver
Takeuchi T, van Vollenhoven R, Ueki Y, Atsumi T, Meerwein S, Bu X, et al. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study. Modern Rheumatology. 2026. doi:10.1093/mr/roag031
BibTeX
@article{Takeuchi2026,
author = {Takeuchi, Tsutomu and van Vollenhoven, Ronald and Ueki, Yukitaka and Atsumi, Tatsuya and Meerwein, Sebastian and Bu, Xianwei and Hirata, Kazuya and Strand, Vibeke},
title = {Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag031}
}
EUVIMED